Canadian Medical Association appoints new CEO
This article was originally published in Scrip
The Canadian Medical Association (CMA), the national association of physicians, has appointed Paul-Emile Cloutier secretary general and chief executive officer, effective next month. Mr Cloutier has served with the CMA for seven years, joining as assistant secretary, general advocacy, communications and public affairs in 2002. He has previously held roles with Via Rail Canada, as director of community and government relations, as well as a number of governmental positions, including intergovernmental affairs at the Ontario government, foreign affairs, and the Federal Department of Immigration.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).